{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:39:52Z","timestamp":1791833992900,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Patients undergoing complex percutaneous coronary intervention (PCI) have an increased risk of cardiovascular events. Whether potent antiplatelet therapy after complex PCI improves outcomes in patients with stable coronary artery disease (SCAD) remains unclear.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> To assess the efficacy and safety of ticagrelor <jats:italic>vs<\/jats:italic>. clopidogrel in patients with SCAD undergoing complex PCI.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients with a diagnosis of SCAD and undergoing PCI during January 2016 to December 2018 were selected from an institutional registry. The primary efficacy endpoint was major adverse cardiac events (MACE) within 12 months after PCI. The primary safety endpoint was major bleeding.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among 15,459 patients with SCAD included in this analysis, complex PCI was performed in 6,335 (41.0%) patients. Of patients undergoing complex PCI, 1,123 patients (17.7%) were treated with ticagrelor. The primary efficacy outcome after complex PCI occurred in 8.6% of patients in the ticagrelor group and 11.2% in the clopidogrel group. Compared with clopidogrel, ticagrelor decreased the risk of MACE in patients undergoing complex PCI [adjusted hazard ratio (HR): 0.764; 95% confidence interval (CI): 0.615 to 0.949; <jats:italic>p<\/jats:italic> = 0.015], but not in non-complex PCI (<jats:italic>p<\/jats:italic> for interaction = 0.001). There was no significant difference in incidence of major bleeding between patients treated with ticagrelor and clopidogrel (<jats:italic>p<\/jats:italic> = 0.221), while ticagrelor was associated with an increased risk of minor bleeding (adjusted HR: 3.099; 95% CI: 2.049 to 4.687; <jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In patients with SCAD and undergoing complex PCI, ticagrelor could substantially reduce the risk of adverse cardiovascular outcomes without increasing the risk of major bleeding compared with clopidogrel.<\/jats:p>","DOI":"10.3389\/fcvm.2021.768190","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T06:35:45Z","timestamp":1637562945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Ziwei","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runlin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx638","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","article-title":"Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update","volume":"54","author":"Teng","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy855","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jacc.2017.07.768","article-title":"Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54","volume":"70","author":"Bonaca","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/eurheartj\/ehz453","article-title":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the global leaders trial","volume":"40","author":"Serruys","year":"2019","journal-title":"Eur Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.12.019","article-title":"Prognosis of patients with stable coronary artery disease (from the CORONOR study)","volume":"113","author":"Bauters","year":"2014","journal-title":"Am J Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.gheart.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jacc.2017.09.011","article-title":"Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention","volume":"70","author":"Yeh","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2018.03.103","article-title":"Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation","volume":"268","author":"G\u00e9n\u00e9reux","year":"2018","journal-title":"Int J Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2018.05.044","article-title":"Defining PCI complexity in the contemporary DES era: clarity or confusion?","volume":"268","author":"Baber","year":"2018","journal-title":"Int J Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.116.022061","article-title":"Treatment of higher-risk patients with an indication for revascularization: evolution within the field of contemporary percutaneous coronary intervention","volume":"134","author":"Kirtane","year":"2016","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jcin.2018.12.005","article-title":"Validation of high-risk features for stent-related ischemic events as endorsed by the 2017 DAPT guidelines","volume":"12","author":"Ueki","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"key":"B18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11739-020-02404-1","article-title":"Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry","volume":"16","author":"Gragnano","year":"2021","journal-title":"Intern Emerg Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","article-title":"Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"324","author":"You","year":"2020","journal-title":"JAMA."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/cpt.2011","article-title":"Efficacy and safety of ticagrelor vs. clopidogrel in East Asian patients with acute myocardial infarction: a nationwide cohort study","volume":"109","author":"Chang","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u201cEast asian paradox\u201d: challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome","volume":"16","author":"Jeong","year":"2014","journal-title":"Curr Cardiol Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","article-title":"Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial","volume":"396","author":"Silvain","year":"2020","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e008649","DOI":"10.1161\/CIRCINTERVENTIONS.119.008649","article-title":"Randomized comparison of intensified and standard P2Y(12)-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial","volume":"13","author":"Mehilli","year":"2020","journal-title":"Circ Cardiovasc Interv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e015560","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the global leaders trial","volume":"10","author":"Vranckx","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1825364","article-title":"Efficacy and safety of ticagrelor and clopidogrel in patients with stable coronary artery disease undergoing percutaneous coronary intervention","author":"Li","year":"2020","journal-title":"J Atheroscler Thromb."},{"key":"B32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/heartjnl-2011-300129","article-title":"Use of risk scores in acute coronary syndromes","volume":"98","author":"Bueno","year":"2012","journal-title":"Heart."},{"key":"B33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10557-020-06956-4","article-title":"Ticagrelor versus clopidogrel in patients with two CYP2C19 loss-of-function alleles undergoing percutaneous coronary intervention","volume":"34","author":"Xi","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ehjcvp\/pvaa038","article-title":"P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients","volume":"7","author":"Bianco","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"Bmj."},{"key":"B36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/eurheartj\/ehs149","article-title":"Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study","volume":"34","author":"Nikolic","year":"2013","journal-title":"Eur Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.clinthera.2013.06.015","article-title":"Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes","volume":"35","author":"Liew","year":"2013","journal-title":"Clin Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1007\/s12325-021-01743-5","article-title":"Cost-effectiveness of ticagrelor compared with clopidogrel in patients with acute coronary syndrome from vietnamese healthcare payers' perspective","volume":"38","author":"Thi Thu Nguyen","year":"2021","journal-title":"Adv Ther."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.768190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T06:35:47Z","timestamp":1637562947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.768190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2021.768190"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.768190","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"article-number":"768190"}}